Repaglinide(re pag’ lah nyde)
GlucoNorm (CAN), Prandin
PREGNANCY CATEGORY C
Drug Classes
Antidiabetic
Meglitinide
Therapeutic Actions
Closes potassium channels in the beta cells of the pancreas, which causes the opening of calcium channels and a resultant increase in insulin release; highly selective for beta cells in the pancreas. Glucose-lowering abilities depend on the existence of functioning beta cells in the pancreas.
Indications
Adjunct to diet and exercise to lower blood glucose in patients with type 2 diabetes mellitus whose hyperglycemia cannot be managed by diet and exercise alone
Combination therapy with metformin or thiazolidinediones to lower blood glucose in patients whose hyperglycemia cannot be controlled by diet and exercise plus monotherapy with any of the following agents alone: Metformin, sulfonylureas, or thiazolidinediones
Contraindications and Cautions
Contraindicated with hypersensitivity to the drug, diabetic ketoacidosis, type 1 diabetes, lactation.
Use cautiously with renal or hepatic impairment, pregnancy.
Available Forms
Tablets—0.5, 1, 2 mg
Dosages
Adults
0.5–4 mg PO taken tid or qid 15–30 min (usually within 15 min) before meals; determine dosage based on patient response; maximum dose is 16 mg/day. Monitor patient regularly and adjust dosage as needed, waiting 1 wk between dose adjustments to assess patient response.
Pediatric patients
Safety and efficacy not established.
Patients with renal or hepatic impairment
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
